You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,915,643


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,915,643
Title:Spatial orientation determination in portable clinical analysis systems
Abstract: The present invention covers the integration and utility of accelerometer features into a clinical analysis system. For example, measurement of dynamic acceleration and orientation of a blood-testing instrument with respect to Earth\'s gravitational field may be used to determine reliability of a test procedure and optionally to provide corrective elements thereof.
Inventor(s): Vandersleen; Gary (Plainsboro, NJ), Emeric; Pierre (Princeton, NJ), Wasserman; Paul (Oakhurst, NJ), Soman; Narendra (Hillsborough, NJ), Davis; Graham (Princeton, NJ)
Assignee: Abbott Point of Care Inc. (Princeton, NJ)
Application Number:15/291,454
Patent Claims:1. A method of performing an analytical test on a test sample, the method comprising: initiating, by an analyzer, a test cycle of a test device, the test cycle comprising a plurality of steps for performing on the test sample the analytical test for at least one target analyte; determining spatial orientation of the analyzer during the test cycle; comparing the determined spatial orientation to a threshold operating spatial plane for the test device, wherein the threshold operating special plane is a predetermined threshold plane for operating the test device during the test cycle; and providing an alert that at least one of instructs and illustrates corrective action including required movement of the analyzer to bring the spatial orientation of the analyzer during the test cycle within the threshold operating spatial plane in order to prompt a user to take the corrective action for the test device during the test cycle, when the determined spatial orientation exceeds the threshold operating spatial plane, wherein the analyzer comprises a processor, a computer readable memory, a non-transitory computer readable storage medium and program instructions, stored on the non-transitory computer readable storage medium for execution by the processor via the computer readable memory, to provide the alert and to receive the corrective action prior to the test cycle ending with a determination of a result of the analytical test.

2. The method of claim 1, further comprising receiving the corrective action for the test device prior to the test cycle ending.

3. The method of claim 1, further comprising correcting the result of the analytical test, when the determined spatial orientation during the test cycle exceeds the threshold operating spatial plane.

4. The method of claim 1, wherein the at least one target analyte is selected from the group consisting of: hematocrit, troponin, creatine kinase myocardial band (CKMB), brain natriuretic peptide (BNP), beta human chorionic gonadotropin (bHCG), carbon dioxide partial pressure (pCO.sub.2), partial pressure oxygen (pO.sub.2), pH, prothrombin time (PT), activated clotting time (ACT), activated partial thromboplastin time (APTT), sodium, potassium, chloride, calcium, urea, glucose, creatinine, lactate, oxygen, and carbon dioxide.

5. The method of claim 1, further comprising: determining motion of the analyzer during the test cycle; comparing the determined motion to a predetermined threshold rate of motion for operating the test device during the test cycle; and at least one of: (i) providing a different alert prompting the user to take different corrective action for the test device during the test cycle, and (ii) suppressing the result of the analytical test, when the determined motion during the test cycle exceeds the predetermined threshold rate of motion.

6. The method of claim 1, further comprising receiving the test sample into the test device.

7. The method of claim 1, wherein the comparing the determined spatial orientation to the threshold operating spatial plane comprises at least one of: comparing the determined roll of the analyzer to a threshold roll; comparing the determined pitch of the analyzer to a threshold pitch; comparing the determined yaw of the analyzer to a threshold yaw; and the providing the alert is performed, when at least one of: (i) the determined roll of the analyzer exceeds the threshold roll, (ii) the determined pitch of the analyzer exceeds the threshold pitch, and (iii) the determined yaw of the analyzer exceeds the threshold yaw.

8. A method of performing an analytical test on a test sample, the method comprising: initiating, by an analyzer, a test cycle of a test device, the test cycle of the test device comprising a plurality of steps for performing on the test sample the analytical test for at least one target analyte; determining motion of the analyzer during the test cycle; comparing during the test cycle the determined motion to a predetermined threshold for operating the test device during the test cycle; and providing an alert that at least one of instructs and illustrates corrective action including cessation or deceleration of movement of the analyzer to bring the motion of the analyzer during the test cycle within the predetermined threshold for the test device in order to prompt a user to take the corrective action for the test device during the test cycle, when the determined motion exceeds the predetermined threshold, wherein the analyzer comprises a processor, a computer readable memory, a non-transitory computer readable storage medium and program instructions, stored on the non-transitory computer readable storage medium for execution by the processor via the computer readable memory, to provide the alert and to receive the corrective action prior to the test cycle ending with a determination of a result of the analytical test.

9. The method of claim 8, further comprising receiving the corrective action for the test device prior to the test cycle ending.

10. The method of claim 8, further comprising correcting the result of the analytical test, when the determined motion during the test cycle exceeds the predetermined threshold.

11. The method of claim 8, wherein the at least one target analyte is selected from the group consisting of: hematocrit, troponin, creatine kinase myocardial band (CKMB), brain natriuretic peptide (BNP), beta human chorionic gonadotropin (bHCG), carbon dioxide partial pressure (pCO.sub.2), partial pressure oxygen (pO.sub.2), pH, prothrombin time (PT), activated clotting time (ACT), activated partial thromboplastin time (APTT), sodium, potassium, chloride, calcium, urea, glucose, creatinine, lactate, oxygen, and carbon dioxide.

12. The method of claim 1, further comprising detecting the at least one target analyte during the test cycle.

13. The method of claim 1, wherein the test sample comprises whole blood.

14. The method of claim 1, wherein the test device is a cartridge comprising a sensor for the at least one target analyte.

15. The method of claim 1, further comprising, prior to the initiating step, inserting the test device into the analyzer.

16. The method of claim 8, further comprising detecting the at least one target analyte during the test cycle.

17. The method of claim 8, wherein the test sample comprises whole blood.

18. The method of claim 8, wherein the test device is a cartridge comprising a sensor for the at least one target analyte.

19. The method of claim 8, further comprising, prior to the initiating step, inserting the test device into the analyzer.

20. The method of claim 8, further comprising receiving the test sample into the test device.

Details for Patent 9,915,643

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 01/15/1974 ⤷  Try a Trial 2032-12-17
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 12/27/1984 ⤷  Try a Trial 2032-12-17
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/15/1985 ⤷  Try a Trial 2032-12-17
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/16/1990 ⤷  Try a Trial 2032-12-17
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 03/26/1974 ⤷  Try a Trial 2032-12-17
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 03/05/1973 ⤷  Try a Trial 2032-12-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.